U.S. Markets closed

Sage’s Brexanolone IV: FDA Grants Priority Review

Mike Benson
Sage’s Brexanolone IV: FDA Grants Priority Review

Sage Therapeutics (SAGE) is a US-based clinical-stage biopharmaceutical company. On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV. The FDA granted a priority review for the drug. Following the news, the stock price increased ~1.8% to the closing price of $154.54 on May 30.